BR112012007635A2 - derivados de feniloxadiazol como inibidores de pgds - Google Patents

derivados de feniloxadiazol como inibidores de pgds

Info

Publication number
BR112012007635A2
BR112012007635A2 BR112012007635A BR112012007635A BR112012007635A2 BR 112012007635 A2 BR112012007635 A2 BR 112012007635A2 BR 112012007635 A BR112012007635 A BR 112012007635A BR 112012007635 A BR112012007635 A BR 112012007635A BR 112012007635 A2 BR112012007635 A2 BR 112012007635A2
Authority
BR
Brazil
Prior art keywords
compound
pgds inhibitors
phenyloxadiazole
derivatives
phenyloxadiazole derivatives
Prior art date
Application number
BR112012007635A
Other languages
English (en)
Other versions
BR112012007635B1 (pt
Inventor
Hillegass Andrea
L Vandeusen Christopher
J Weiberth Franz
Lee George
S Gill Harpal
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112012007635A2 publication Critical patent/BR112012007635A2/pt
Publication of BR112012007635B1 publication Critical patent/BR112012007635B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

derivados de feniloxadiazol como inibidores de pgds. a presente invenção refere-se a um composto de fórmula (i): em que r1, r2 e r3 são tal como aqui definidos, uma composição farmacêutica compreendendo o composto, intermediários e processos para a produção dos ditos compostos, e ao uso do composto para tratar distúrbios alérgicos e/ou inflamatórios, particularmente distúrbios como rinite alérgica, asma, doença pulmonar obstrutiva crônica (copd) e degeneração macular relacionada com a idade (amd).
BR112012007635-3A 2009-10-08 2010-10-07 Compostos derivados de feniloxadiazol como inibidores de pgds, composição farmacêutica compreendendo os mesmos e seus processos de preparação BR112012007635B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24969309P 2009-10-08 2009-10-08
US61/249,693 2009-10-08
FR1056094 2010-07-26
FR1056094 2010-07-26
PCT/US2010/051727 WO2011044307A1 (en) 2009-10-08 2010-10-07 Phenyloxadiazole derivatives as pgds inhibitors

Publications (2)

Publication Number Publication Date
BR112012007635A2 true BR112012007635A2 (pt) 2017-06-20
BR112012007635B1 BR112012007635B1 (pt) 2019-07-09

Family

ID=43606440

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007635-3A BR112012007635B1 (pt) 2009-10-08 2010-10-07 Compostos derivados de feniloxadiazol como inibidores de pgds, composição farmacêutica compreendendo os mesmos e seus processos de preparação

Country Status (21)

Country Link
US (5) US9469627B2 (pt)
EP (1) EP2486024B1 (pt)
JP (2) JP5753176B2 (pt)
KR (1) KR101701135B1 (pt)
CN (3) CN107875155A (pt)
AR (1) AR078552A1 (pt)
AU (1) AU2010303439B2 (pt)
BR (1) BR112012007635B1 (pt)
CA (1) CA2776242C (pt)
DK (1) DK2486024T3 (pt)
ES (1) ES2543011T3 (pt)
IL (1) IL218967A (pt)
MA (1) MA33725B1 (pt)
MX (1) MX2012003021A (pt)
NZ (1) NZ599099A (pt)
PH (1) PH12012500676A1 (pt)
RU (2) RU2572608C2 (pt)
SG (1) SG179199A1 (pt)
TW (1) TWI508960B (pt)
UY (1) UY32938A (pt)
WO (1) WO2011044307A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107875155A (zh) 2009-10-08 2018-04-06 赛诺菲 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
CN108430992A (zh) 2015-12-17 2018-08-21 阿斯特克斯医疗公司 作为h-pgds抑制剂的喹啉-3-甲酰胺
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
EP3630738B1 (en) * 2017-05-22 2023-07-19 Egis Gyógyszergyár Zrt. Process for the production of ozanimod
EP3638672A1 (en) 2017-06-13 2020-04-22 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors
CA3085293A1 (en) 2017-12-13 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h-pgds
JP2022506850A (ja) 2018-11-08 2022-01-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 化学化合物
WO2021256569A1 (ja) * 2020-06-19 2021-12-23 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害する縮環化合物
CA3240926A1 (en) 2021-12-17 2023-06-22 Sato Pharmaceutical Co., Ltd. Azaindole derivative inhibiting h-pgds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5176132A (en) 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
DE10117823A1 (de) 2001-04-10 2002-10-17 Merck Patent Gmbh Oxalsäurederivate
ATE516277T1 (de) * 2002-03-19 2011-07-15 Ono Pharmaceutical Co Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten
IL166782A0 (en) 2002-08-16 2006-01-15 Aventis Pharma Inc Method for assaying compounds or agents for ability to decrease the activity of microsomal prostaglandin e synthase or hematopoietic prostaglandin d synthase
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
WO2005094805A1 (ja) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
EP1745047B1 (en) * 2004-04-21 2010-03-24 Schering Corporation Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists
JP5209181B2 (ja) * 2005-03-15 2013-06-12 富士フイルム株式会社 化合物、組成物、位相差板、楕円偏光板および液晶表示装置
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2007051121A (ja) * 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
CN100556905C (zh) * 2005-09-08 2009-11-04 国家南方农药创制中心江苏基地 吡唑酰胺类化合物及其中间体和以该类化合物为活性成分的有害生物防治剂
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
PE20110118A1 (es) 2005-10-04 2011-03-08 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
EP2129660A2 (en) 2006-12-19 2009-12-09 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
JP2010519328A (ja) 2007-02-26 2010-06-03 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンｄ２が媒介する疾患の治療のためのそれらの使用
DK2142516T3 (da) 2007-03-30 2013-04-15 Sanofi Sa Pyrimidinhydrazidforbindelser i ders egenskab af pgds-inhibitorer
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
TW201034675A (en) * 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
US9058931B2 (en) 2009-01-12 2015-06-16 The United States Of America, As Represented By The Secretary Of The Navy Composite electrode structure
CN107875155A (zh) * 2009-10-08 2018-04-06 赛诺菲 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途

Also Published As

Publication number Publication date
JP2013507376A (ja) 2013-03-04
IL218967A0 (en) 2012-07-31
EP2486024B1 (en) 2015-04-22
KR20120094910A (ko) 2012-08-27
RU2012118756A (ru) 2013-11-20
CN102666508A (zh) 2012-09-12
CA2776242C (en) 2014-09-02
AU2010303439A1 (en) 2012-04-26
US20230190747A1 (en) 2023-06-22
RU2015151129A (ru) 2019-01-15
JP5897186B2 (ja) 2016-03-30
IL218967A (en) 2015-05-31
CN107875155A (zh) 2018-04-06
PH12012500676A1 (en) 2015-06-03
US20120190695A1 (en) 2012-07-26
UY32938A (es) 2011-05-31
MA33725B1 (fr) 2012-11-01
US9937175B2 (en) 2018-04-10
MX2012003021A (es) 2012-04-10
JP5753176B2 (ja) 2015-07-22
US20170231990A1 (en) 2017-08-17
US9469627B2 (en) 2016-10-18
NZ599099A (en) 2013-05-31
KR101701135B1 (ko) 2017-02-01
RU2572608C2 (ru) 2016-01-20
AU2010303439B2 (en) 2015-10-29
RU2015151129A3 (pt) 2019-07-17
ES2543011T3 (es) 2015-08-13
JP2015178516A (ja) 2015-10-08
AR078552A1 (es) 2011-11-16
EP2486024A1 (en) 2012-08-15
BR112012007635B1 (pt) 2019-07-09
DK2486024T3 (en) 2015-07-27
US20190000845A1 (en) 2019-01-03
SG179199A1 (en) 2012-04-27
US20190262338A1 (en) 2019-08-29
CA2776242A1 (en) 2011-04-14
HK1173441A1 (en) 2013-05-16
TW201127835A (en) 2011-08-16
CN106943407A (zh) 2017-07-14
TWI508960B (zh) 2015-11-21
WO2011044307A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
BR112012007635A2 (pt) derivados de feniloxadiazol como inibidores de pgds
UY29840A1 (es) Compuestos de pirimidina amida como inhibidores de pgds
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
BR112014007721A2 (pt) processos para preparar compostos úteis como inibidores de atr quinase
BR112014002202A2 (pt) macrociclos como inibidores de fator xia
BR112013023517A2 (pt) "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica"
ECSP088741A (es) Derivados de benzotriazol como agonistas del adrenoreceptor beta2
BR112014007694A2 (pt) 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)óxi)naftaleno-1-il)ureias como inibidores de p38 map cinase
SV2009002861A (es) Compuestos de pirimidina amida como inhibidores de pgds
BR112015002118A2 (pt) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
GT200900289A (es) Compuestos organicos.-
CL2007002159A1 (es) Uso de compuestos derivados de quinuclidina para tratar enfermedades tales como asma, enfermedad obstructiva cronica, bronquitis cronica, tos y enfisema; compuestos derivados de quinuclidina; composicion farmaceutica que comprende a dichos compuestos.
CL2011002461A1 (es) Compuestos derivados de tipo amida de compuestos [3,2-c] pirazol con actividad glucocorticoide utiles en condiciones inflamatorias y alergicas como asma, epoc o rinitis alergica.
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
MX350862B (es) Acidos de piperidinil naftilacetico.
CL2008003495A1 (es) Compuestos derivados de pirazol; composicion farmaceutica, metodo de preparacion y; su uso para tratar una enfermedad mediada por 5-lo tal como asma, broncocontriccion, enfisema, enfermedades obstructivas o inflamatorias de las vias respiratorias, bronquitis, lesion pulmonar aguda, bronquiectasia, rinitis alergica, entre otras.
BR112021020279A2 (pt) Derivados de piridopirimidinas como inibidores de p2x3
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase
BR112013000042A2 (pt) composto para inibição da fosfodiesterase tipo 5 e método de preparação do mesmo
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
BR112013020510A2 (pt) inibidores de catepsina c
CR11666A (es) Farmacoforos duales- antagonistas muscarinicos pdea
CL2012000885A1 (es) Compuestos derivados de feniloxadiazol, inhibidores de las prostaglandinas sintasa (pgds); procedimiento de preparacion de dichos compuestos; compuestos intermediarios; composicion farmaceutica que comprende dichos compuestos, util para tratar un trastorno inflamatorio o alergico.
UY30988A1 (es) Compuestos de pirimidina hidrazida como inhibidores de pgds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/10/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/10/2010, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2848 DE 05-08-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.